Get Your Personalized Supplement StackSupplement Stack Quiz

Bifidobacteria Longum

Also known as: Bifidobacteria Longum, B. longum, *Bifidobacterium longum*

Overview

*Bifidobacterium longum* is a species of probiotic bacteria that plays a crucial role in gut health. It is naturally found in the intestines of humans and is extensively studied for its beneficial effects, particularly in neonatal care and digestive health. This probiotic is commonly used to prevent and manage various gastrointestinal disorders such as necrotizing enterocolitis (NEC) in preterm infants and irritable bowel syndrome (IBS) in adults. It is available in various forms, including capsules and powders. The current research is moderately mature, with several systematic reviews and meta-analyses highlighting its effects, yet more studies are needed to clarify its efficacy across different populations and conditions.

Benefits

The primary benefits of *Bifidobacterium longum* include a significant reduction in the risk of necrotizing enterocolitis (NEC) in infants, backed by a meta-analysis that shows a risk ratio of 0.539 (95% CI: 0.333, 0.874). Additionally, systematic reviews indicate that *B. longum* 35624 can improve symptoms of irritable bowel syndrome (IBS) and enhance quality of life, particularly with prolonged treatment. For gut health, *B. longum* BB536 has been shown to effectively regulate bowel movements in both healthy individuals and those experiencing IBS. Populations that benefit the most include preterm infants at risk for NEC and adults suffering from IBS. Evidence strength ranges from moderate to strong, particularly for NEC risk reduction.

How it works

*Bifidobacterium longum* primarily works through the modulation of gut microbiota composition, supporting a balanced microbial environment. It produces short-chain fatty acids, which are beneficial for gut health and inflammation. It also interacts with gut epithelial cells and various components of the immune system, enhancing gut barrier function and regulating immune responses. The colonization of the gut is critical, as this allows the probiotic to exert its beneficial effects.

Side effects

*Bifidobacterium longum* is generally considered safe, with no consistently reported common side effects. Mild gastrointestinal disturbances may occur in 1-5% of users, while serious adverse effects, such as systemic infections, are extremely rare and primarily concern immunocompromised individuals. It is advisable for those with weakened immune systems to exercise caution when considering this probiotic. Furthermore, there are no significant drug interactions reported, making it a suitable option for many; however, safety precautions should still be observed in special populations such as premature infants.

Dosage

The effective dosage of *Bifidobacterium longum* often ranges from 10^8 to 10^{10} CFU per day, depending on the desired outcomes. For the treatment of IBS, an optimal dosage around 10^9 CFU per day is recommended. There is no established maximum safe dose, but higher dosages are typically considered safe within standard ranges. Continuous use over several weeks to months may be necessary to achieve optimal results. Common forms of administration include capsules and powders, both of which are designed to facilitate gut colonization, which is key to their efficacy.

FAQs

How should I store *Bifidobacterium longum* supplements?

Store in a cool, dry place, preferably in the refrigerator, to maintain the viability of the probiotic.

Is *Bifidobacterium longum* safe for everyone?

Generally safe, but those who are immunocompromised should consult a healthcare professional before use.

How long until I see results from using *Bifidobacterium longum*?

Improvement in IBS symptoms typically occurs over several weeks to months with continuous use.

Can *Bifidobacterium longum* cure gastrointestinal issues?

While it can alleviate symptoms, it is not a cure-all; individual responses can vary.

What should I do if I experience side effects?

If you experience any adverse effects, consult a healthcare professional for guidance.

Research Sources

https://www.mdpi.com/2304-8158/12/24/4451/review_report – This meta-analysis evaluates the impact of *Bifidobacterium longum* on NEC in preterm infants, concluding that it significantly reduces the risk with a clear risk ratio and highlighting the quality and consistency of studies.
https://pubmed.ncbi.nlm.nih.gov/38137255/ – This systematic review examines the effects of *B. longum* 35624 on IBS patients, revealing significant improvements in symptoms and quality of life, although variability in study designs was noted.
https://www.microbiotajournal.com/article/998 – A randomized controlled trial found that *B. longum* BB536 effectively regulates bowel movements, although the study's small sample size limits its generalizability.
https://pubmed.ncbi.nlm.nih.gov/36382178/ – This study supports the overall benefits of *Bifidobacterium longum*, reinforcing its role in gut health based on comprehensive clinical data.
https://www.microbiotajournal.com/wp-content/uploads/sites/7/2024/06/e998.pdf – A review highlighting the various strains of *Bifidobacterium longum* and their respective health benefits, emphasizing the need for further research in diverse populations.